Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Next Previous
Trial Profile

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Leronlimab (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CytoDyn

    • Most Recent Events

    • 07 Jun 2022 Results of pooled analysis from NCT03838367, NCT04313075, NCT04504942; exploring the effect of leronlimab on circulating tumor associated cells (TACs) from peripheral blood as a surrogate and early predictor of drug response, presented at the 58th Annual Meeting of the American Society of Clinical Oncolog
    • 13 Apr 2022 Blood sample from 3 studies (NCT03838367, NCT04313075 & NCT04504942) were used to assess the predictive value of TACs, measured by the LifeTracDx assay, presented at the 113th Annual Meeting of the American Association for Cancer Research.
    • 18 Mar 2022 Planned End Date changed from 16 Jun 2022 to 16 Sep 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top